肝硬化患者肝细胞癌监测的使用:系统综述与荟萃分析
该系统综述与荟萃分析纳入29项队列研究、共118,799例肝硬化患者,评估肝细胞癌监测的使用率及干预措施效果。汇总监测使用率为24.0%(95%CI 18.4-30.1),专科消化/肝病门诊最高(73.7%),人群队列最低(8.8%)。八项评估教育、内联提醒和人群外展干预的研究均报告监测使用率显著提高(范围9.4%-63.6%)。
要点
- 肝硬化患者HCC监测总体使用率仅24.0%,临床实践中仍严重不足。
- 专科消化/肝病门诊监测率73.7%,人群队列仅8.8%,差异显著。
- 酒精相关或NASH相关肝硬化患者监测使用率更低。
核心结论
- 肝细胞癌监测在肝硬化患者中仍使用不足,尤其在酒精相关或NASH相关肝硬化及非专科消化门诊随访者中。
- 提供者教育、内联提醒系统和人群健康外展等干预可显著提高监测使用率。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE数据库2010年1月至2018年8月的队列研究。
- 共纳入29项研究,总计118,799例肝硬化患者。
主要发现
- 汇总监测使用率为24.0%(95%CI 18.4-30.1)。
- 专科消化/肝病门诊研究监测率最高为73.7%,人群队列研究最低为8.8%(P<0.001)。
- 常见相关因素:专科医师随访者监测率更高,酒精相关或NASH相关肝硬化患者监测率更低。
- 八项评估干预的研究(n=5,229)均报告监测使用率显著增加,范围9.4%-63.6%。
关键数值与推荐
- 监测使用率汇总估计:24.0%(95%CI 18.4-30.1)。
- 专科消化/肝病门诊监测率73.7%,人群队列8.8%(P<0.001)。
- 干预后监测率增加范围9.4%-63.6%。
临床怎么用
- 应重点关注酒精相关或NASH相关肝硬化及非专科随访患者的HCC监测实施。
- 可采用提供者教育、提醒与召回系统及人群健康外展策略提高监测率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) surveillance is associated with early tumor detection and improved survival; however, it is often underused in clinical practice. We aimed to characterize surveillance use among patients with cirrhosis and the efficacy of interventions to increase surveillance. APPROACH AND RESULTS: We performed a systematic literature review using the MEDLINE database from January 2010 through August 2018 to identify cohort studies evaluating HCC surveillance receipt or interventions to increase surveillance in patients with cirrhosis. A pooled estimate for surveillance receipt with 95% confidence intervals was calculated. Correlates of surveillance use were defined from each study and prespecified subgroup analyses. Twenty-nine studies, with a total of 118,799 patients, met inclusion criteria, with a pooled estimate for surveillance use of 24.0% (95% confidence interval, 18.4-30.1). In subgroup analyses, the highest surveillance receipt was reported in studies with patients enrolled from subspecialty gastroenterology/hepatology clinics and lowest in studies characterizing surveillance in population-based cohorts (73.7% versus 8.8%, P < 0.001). Commonly reported correlates of surveillance included higher receipt among patients followed by subspecialists and lower receipt among those with alcohol-associated or nonalcoholic steatohepatitis (NASH)-related cirrhosis. All eight studies (n = 5,229) evaluating interventions including patient/provider education, inreach (e.g., reminder and recall systems), and population health outreach strategies reported significant increases (range 9.4%-63.6%) in surveillance receipt. CONCLUSIONS: HCC surveillance remains underused in clinical practice, particularly among patients with alcohol-associated or NASH-related cirrhosis and those not followed in subspecialty gastroenterology clinics. Interventions such as provider education, inreach including reminder systems, and population health outreach efforts can significantly increase HCC surveillance.
引用
- Wolf E, Rich NE, Marrero JA, et al. Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. Hepatology. 2020. PMID: 32383272. doi:10.1002/hep.31309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。